Bisphosphonates (BPs) are potent inhibitors of osteoclast-mediated bone resorption and are widely used in the treatment of bone metastases. Osteonecrosis of the jaw (ONJ) is the worst side-effect related to BP use. At our Center, we have implemented internal guidelines regarding the management of patients with bone metastases from solid tumors. Our analysis includes 200 patients affected by solid tumors with bone metastases who received zoledronic acid. They underwent a baseline mouth assessment to evaluate their dental conditions and to perform dental care; a dental follow-up was performed every six months. All patients received calcium and vitamin D daily. Dental examination and application of preventive measures led to a total reduction in ONJ in our patients treated with zoledronic acid. The keystone in management of ONJ is prevention, and the risk of developing ONJ during treatment with zoledronic acid is reduced by implementing preventive measures.

Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates / DE IULIIS, Francesca; Taglieri, Ludovica; Amoroso, Lucrezia; Vendittozzi, Stefania; Blasi, Luciana; Salerno, Gerardo; Lanza, Rosina; Scarpa, Susanna. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - STAMPA. - 34:5(2014), pp. 2477-2480.

Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates

DE IULIIS, FRANCESCA;Taglieri, Ludovica;AMOROSO, LUCREZIA;VENDITTOZZI, STEFANIA;BLASI, LUCIANA;Salerno, Gerardo;SCARPA, Susanna
2014

Abstract

Bisphosphonates (BPs) are potent inhibitors of osteoclast-mediated bone resorption and are widely used in the treatment of bone metastases. Osteonecrosis of the jaw (ONJ) is the worst side-effect related to BP use. At our Center, we have implemented internal guidelines regarding the management of patients with bone metastases from solid tumors. Our analysis includes 200 patients affected by solid tumors with bone metastases who received zoledronic acid. They underwent a baseline mouth assessment to evaluate their dental conditions and to perform dental care; a dental follow-up was performed every six months. All patients received calcium and vitamin D daily. Dental examination and application of preventive measures led to a total reduction in ONJ in our patients treated with zoledronic acid. The keystone in management of ONJ is prevention, and the risk of developing ONJ during treatment with zoledronic acid is reduced by implementing preventive measures.
2014
zoledronic acid; bone metastasis; osteonecrosis of the jaw; bisphosphonates
01 Pubblicazione su rivista::01a Articolo in rivista
Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates / DE IULIIS, Francesca; Taglieri, Ludovica; Amoroso, Lucrezia; Vendittozzi, Stefania; Blasi, Luciana; Salerno, Gerardo; Lanza, Rosina; Scarpa, Susanna. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - STAMPA. - 34:5(2014), pp. 2477-2480.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/553874
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 14
social impact